Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Al Mann Dies, Leaves Legacy Beyond MannKind

This article was originally published in Scrip

Executive Summary

MannKind Corp. founder and recently named chairman emeritus Alfred Mann died on Feb. 25, leaving behind a biomedical legacy that extends far beyond his namesake company.

You may also be interested in...

Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis

Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016

Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.

ADA: MannKind Has Evolved Rapidly To Accommodate Confident Afrezza Relaunch

Six months ago it seemed as though the sky was falling for small drug developer MannKind, when its big pharma licensing partner, Sanofi, pulled out of their deal for the manufacture and distribution of approved inhaled insulin therapy, Afrezza. However, MannKind Corp. made rapid changes to evolve its business into a specialty pharmaceutical company and took back the drug to market on its own – a feat it had never performed before.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts